Stock News Recap: SCYNEXIS (SCYX)

 Shares of SCYNEXIS (SCYX) were transacted with a volume of 404114 shares in last trading period as compared to its average volume of 378.97K shares over last three months period. The stock price scored -2.52% and valued at $0.72.

SCYNEXIS a USA based Company, belongs to Healthcare sector and Drugs – Generic industry. Shares of the company returned -3.43% during the last five trading days and it returned 70.71% in past 30 trading days. It changed -31.71% over recent three months. The stock has changed -61.03% in one year period and YTD Performance clocked at 48.85%.

SCYNEXIS, Inc. (NASDAQ: SCYX) declared positive results from the first interim efficacy analysis of the ongoing FURI study.

FURI is a Phase 3 open-label study evaluating oral ibrexafungerp as a salvage treatment in patients with difficult-to-treat mucocutaneous and invasive fungal infections that are refractory to or intolerant of currently available standards of care. An independent expert panel (Data Review Committee) assessed the efficacy of ibrexafungerp in the first 20 treated patients. Oral ibrexafungerp showed clinical benefits in 17 out of 20 patients, with 11 patients achieving a complete or partial response and six patients a stable disease response. Only two patients did not respond to ibrexafungerp treatment and the outcome for one patient was considered indeterminate. Along with demonstrating the ability to treat fungal infections in vulnerable patients who failed other therapies, these preliminary results support continued patient enrollment in the FURI study to build toward a future New Drug Application (NDA) submission and potential approval through the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD).

The 20 patients evaluated in this interim analysis suffered from a variety of severe conditions, including esophageal candidiasis, intra-abdominal abscesses, and oropharyngeal candidiasis, with the most common fungal species being Candida glabrata and Candida krusei, two highly resistant organisms. Ibrexafungerp treatment ranged from seven to 90 days, with a mean duration of 36.4 days.

Oral ibrexafungerp was well-tolerated, with the most common treatment-related adverse events being gastrointestinal. There were no deaths due to progressive fungal disease and no safety signals warranting changes in the study.

The price moved ahead 5.11% from the mean of 20 days, 8.58% from 50 and separated -41.38% from 200 days average price. Its price volatility for a month is at 13.36% and for a week, volatility remained at 8.60%. It beta stands at 1.41. Company’s price to sales ratio for last 12 months was 114.79 while its price to book ratio for the most recent quarter was 1.22. Its Market Cap valued at $34.44M.

Leave a Reply

Your email address will not be published. Required fields are marked *